Sustainability & Climate

A junior miner's auditor and finance chief changes signal a calculated move to de-risk its path to becoming a major developer of a 'green' gold mine.

Designer Hiromi Asai redefines Japanese heritage at Miami Art Week, transforming sacred kimono textiles into sculptural menswear and making a bold market play.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

Healthcare tech firm StaffDNA’s title sponsorship of the Cure Bowl is more than a game—it's a calculated move blending branding with a cancer research mission.

Massey Ferguson's award to the World's Oldest Rodeo is more than a gift; it's a strategic look at how heritage brands are powering community impact.

BlackRock has once again boosted its holding in Finnish drugmaker Orion to over 5%. We decode what this calculated move signals for Orion's future.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

Whisker's Litter-Robot is now HSA/FSA eligible, a strategic move redefining medical expenses and giving it a major edge in the booming pet tech market.

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

Canadian startup Tracktile secures funding to democratize AI, offering small food manufacturers the predictive operational tools once reserved for giants.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Getlink's latest figures show a slowdown in cross-Channel traffic, revealing deep strains in the automotive sector and growing consumer caution.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.

Galderma secured stringent EU approval to use its Sculptra biostimulator on the body, targeting a billion-dollar market and setting a new industry benchmark.

As Airbus doubles down in China, the partnership between Paris and Beijing reveals a pragmatic model balancing deep economic ties with a bold geopolitical vision.

A new program uses seismic waves and AI to map soil health at an unprecedented scale and cost, empowering a global movement to heal our planet's foundation.

Immunome is using strategic stock grants to lure top talent. We analyze why this move is critical for its pipeline and what it means for investors.